Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Zevra Therapeutics Inc (ZVRA)

Zevra Therapeutics Inc (ZVRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call GlobeNewswire - Wed Apr 22, 6:30AM CDT

BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease,...

ZVRA : 10.08 (-0.30%)
Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Mar 20, 3:30PM CDT

BOSTON, March 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease,...

ZVRA : 10.08 (-0.30%)
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million GlobeNewswire - Mon Mar 16, 6:30AM CDT

BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease,...

ZVRA : 10.08 (-0.30%)
GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C Business Wire - Tue Mar 10, 7:30AM CDT

Program to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in NPC

ZVRA : 10.08 (-0.30%)
WGS : 68.43 (+3.31%)
Zevra Therapeutics: Q4 Earnings Snapshot AP - Mon Mar 9, 3:40PM CDT

Zevra Therapeutics: Q4 Earnings Snapshot

ZVRA : 10.08 (-0.30%)
Zevra Reports Fourth Quarter and Full Year 2025 Financial Results GlobeNewswire - Mon Mar 9, 3:05PM CDT

Q4 net revenue of $34.1 million, representing 31% growth quarter-over-quarter FY 2025 net revenue of $106.5 million , driven by growth in MIPLYFFA ® net revenue to $87.4 million...

ZVRA : 10.08 (-0.30%)
Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer GlobeNewswire - Thu Mar 5, 6:30AM CST

CELEBRATION, Fla., March 05, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with...

ZVRA : 10.08 (-0.30%)
Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call GlobeNewswire - Mon Mar 2, 6:30AM CST

CELEBRATION, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with...

ZVRA : 10.08 (-0.30%)
Zevra Therapeutics to Present at the Citizens Life Sciences Conference GlobeNewswire - Wed Feb 25, 6:30AM CST

CELEBRATION, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with...

ZVRA : 10.08 (-0.30%)
Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses Business Wire - Wed Feb 18, 12:51PM CST

Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Zevra Therapeutics, Inc. (NASDAQ: ZVRA). The investigation focuses on Zevra’s executive officers and whether investor...

ZVRA : 10.08 (-0.30%)

Barchart Exclusives

Intel Just Hit a New All-Time High. Does INTC Stock Have More Room to Run? Barchart - 19 minutes ago
Intel shares are soaring on better-than-expected Q1 earnings and upbeat future guidance. Evercore ISI analysts recommend buying INTC stock into the post-earnings strength. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.